CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
CNS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.99+0.14 (+2.87%)
Close on Oct 19, 2026
- Market cap
- $34.12M
- P/E (TTM)
- –
- Dividend yield
- –
CNS Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $7.29M | $166.30M |
| Enterprise Value | -$12.69M | $88.19M |
| PB Ratio | 0.40 | 2.03 |
| P/TBV Ratio | 0.40 | 2.29 |
Income (trailing twelve months)
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$16.91M | -$21.40M |
| Net Income | -$16.70M | -$22.46M |
| EBITDA | -$16.91M | -$16.91M |
| EPS (Diluted) | -$23.14 | -$0.83 |
Returns
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -106.6% | -53.2% |
| Return on Assets (ROA) | -91.6% | -40.9% |
| Return on Capital Employed (ROCE) | -92.9% | -38.1% |
Balance sheet
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $19.99M | $61.43M |
| Net Cash (Debt) | $19.99M | $15.35M |
| Net Cash Per Share | $13.67 | $0.66 |
| Equity (Book Value) | $18.20M | $49.09M |
| Book Value Per Share | $12.45 | $1.37 |
| Tangible Book Value | $18.20M | $23.52M |
| Working Capital | $18.19M | $76.81M |
Financial position
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 5.86 | 3.34 |
| Quick Ratio | 5.35 | 2.44 |
| Interest Coverage | -1131.57 | -6.26 |
Cash flow (trailing twelve months)
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.41M | -$12.35M |
Efficiency
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$2.09M | -$703.34K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -229.0% | -23.3% |
Shares
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 1,461,450 | 58,127,000 |
| Shares Change (QoQ) | 80.1% | 0.54% |
| Float | 1,074,380 | 49,136,700 |
| Shares Held by Insiders | 26.5% | 11.6% |
| Shares Held by Institutions | 19.2% | 59.4% |
Scores
| Measure | CNS Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -7.26 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from CNS Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.